Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.

被引：0
|
作者：
Pinto, C.
Di Fabio, F.
Siena, S.
Cascinu, S.
Llimpe, F. L. Rojas
Ceccarelli, C.
Mutri, V.
Giaquinta, S.
Piana, E.
Martoni, A. A.
机构：
[1] S Orsola M Malpighi Hosp, Med Oncol Unit, Bologna, Italy
[2] Osped Niguarda Ca Granda, Med Oncol Unit, Milan, Italy
[3] Torrette Hosp, Med Oncol Unit, Ancona, Italy
[4] S Orsola M Malpighi Hosp, Pathol Unit, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4031
引用
收藏
页码：186S / 186S
页数：1
相关论文
共 50 条
  • [31] Positron emission tomography (18FDG-PET) in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian phase II study
    Di Fabio, F.
    Pinto, C.
    Fanti, S.
    Rojas, Llimpe F.
    Longobardi, C.
    Nanni, C.
    Funaioli, C.
    Ambrosini, V
    Sperandi, F.
    Martoni, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 92 - 92
  • [32] Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
    Assenat, Eric
    Desseigne, Francoise
    Thezenas, Simon
    Viret, Frederic
    Mineur, Laurent
    Kramar, Andrew
    Samalin, Emmanuelle
    Portales, Fabienne
    Bibeau, Frederic
    Crapez-Lopez, Evelyne
    Bleuse, Jean Pierre
    Ychou, Marc
    ONCOLOGIST, 2011, 16 (11): : 1557 - 1564
  • [33] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li Ning
    Li Zhi
    Fu Qiang
    Zhang Bin
    Zhang Jian
    Wan XiangBin
    Lu Chaomin
    Wang Jinbang
    Deng Wenying
    Wei Chen
    Ma Yijie
    Bie Liangyu
    Wang Mengyu
    Luo Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, N.
    Li, Z.
    Fu, Q.
    Zhang, B.
    Zhang, J.
    Wan, X.
    Lu, C.
    Wang, J.
    Deng, W.
    Wei, C.
    Ma, Y.
    Bie, L.
    Wang, M.
    Luo, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1302 - S1302
  • [35] Camrelizumab combined with SOX in the first-line treatment of unresectable advanced or metastatic gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, prospective, and open-label clinical study.
    Liu, Wenlou
    Qin, Xiaobing
    Zhao, Yang
    Ge, Yan
    Tang, Juanjuan
    Wang, Hongmei
    Han, Zhengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16090 - E16090
  • [36] Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
    Babu, K. Govind
    Chaudhuri, Tamojit
    Lakshmaiah, K. C.
    Dasappa, Lokanatha
    Jacob, Linu Abraham
    Babu, M. C. Suresh
    Rudresha, A. H.
    Lokesh, K. N.
    Rajeev, L. K.
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (02) : 85 - 87
  • [37] A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 407 - 407
  • [38] Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study.
    Richards, D. A.
    Kocs, D. M.
    Spira, A. I.
    McCollum, A. D.
    Boehm, K. A.
    Zhan, F.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] SPOTLIGHT: Comparison of zolbetuximab or placebo+mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
    Yamaguchi, K.
    Shitara, K.
    Al-Batran, S-E.
    Bang, Y-J.
    Catenacci, D.
    Enzinger, P.
    Ilson, D.
    Kim, S.
    Lordick, F.
    Shah, M.
    Van Cutsem, E.
    Xu, R-H.
    Arozullah, A.
    Park, J. Wook
    Ajani, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
    Xu, J.
    Jiang, H.
    Pan, Y.
    Gu, K.
    Cang, S.
    Han, L.
    Shu, Y.
    Li, J.
    Zhao, J.
    Pan, H.
    Luo, S.
    Qin, Y.
    Guo, Q.
    Bai, Y.
    Ling, Y.
    Guo, Y.
    Li, Z.
    Liu, Y.
    Wang, Y.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1331 - S1331
12345